EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis

Nadav Weijel, Safwat Odeh, Amjad Mousa, Nina Nazarov, Olga Zelman, Ilana Levy Yurkovski

Case Reports in Oncology · 18.04.2025 · 18 (1) · 613-619

DOI: 10.1159/000545677 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 18.04.2025. Verfasst von Nadav Weijel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine B Department, Bnai Zion Medical Center, Haifa, Israel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Obinutuzumab, an anti-CD20 antibody, is widely used in the treatment of B-cell lymphomas. While diarrhea is a known side effect, obinutuzumab-induced inflammatory bowel disease (IBD)-like conditions are rarely reported. Here, we present a case of obinutuzumab-induced pancolitis. Case Presentation: A 69-year-old male with stage IV follicular lymphoma, treated with obinutuzumab-CHOP and subsequent obinutuzumab maintenance therapy, developed non-bloody diarrhea after his third maintenance dose. Endoscopic and histological findings mimicked Crohn’s disease, leading to a diagnosis of obinutuzumab-induced pancolitis. Obinutuzumab was discontinued, and the patient was transitioned to infliximab therapy, leading to partial improvement.

Conclusion

This case demonstrates a severe instance of obinutuzumab-induced pancolitis with IBD-like features, emphasizing the need for clinicians to consider drug-induced etiologies in patients presenting with new gastrointestinal symptoms during obinutuzumab therapy. Timely diagnosis and a multidisciplinary approach are crucial for effective management. Further reports are needed to better understand the full spectrum of gastrointestinal toxicity associated with obinutuzumab and guide future treatment.

Schlagwörter

Stichwörter der Autor:innen

ColitisInflammatory bowel diseaseLymphomaObinutuzumab

Autor:innen und Institutionen

  • Internal Medicine B Department, Bnai Zion Medical Center, Haifa, Israel.
  • Gastroenterology Unit, Bnai Zion Medical Center, Haifa, Israel.
  • Pathology Department, Bnai Zion Medical Center, Haifa, Israel.
  • Radiology Department, Bnai Zion Medical Center, Haifa, Israel.
  • Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.

Zitieren

APA

Weijel, N., Odeh, S., Mousa, A., Nazarov, N., Zelman, O., & Yurkovski, I. L. (2025). Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis. Case Reports in Oncology, 18(1), 613-619. https://doi.org/10.1159/000545677

Vancouver

Weijel N, Odeh S, Mousa A, Nazarov N, Zelman O, Yurkovski IL. Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis. Case Reports in Oncology. 2025;18(1):613-619. doi:10.1159/000545677

BibTeX
@article{Weijel2025,
  author = {Weijel, Nadav and Odeh, Safwat and Mousa, Amjad and Nazarov, Nina and Zelman, Olga and Yurkovski, Ilana Levy},
  title = {Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis},
  journal = {Case Reports in Oncology},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {613--619},
  doi = {10.1159/000545677}
}
Kostenlos starten →